Martin Andrew, GSK’s Senior Vice President Rare Diseases, spoke to us about the EMA’s Adaptive Licensing Pilot Scheme, which GSK has had a program accepted into. In this report Martin discussed the positives and negatives of the Adaptive Licensing scheme and the UK’s Early Access to Medicine Scheme (EAMS).
This report covers:
- How the Adaptive Licensing scheme will move forward
- The EAMS scheme and its drawbacks
- Is enough currently being done to provide adequate access for potentially lifesaving drugs?
…and much more
If you are interested in hearing more from Martin about the Adaptive Licensing Pilot Scheme, join us for the Fast Tracking Orphan Drugs Briefing on 10th July 2014 in London where he will be delivering a presentation on this very topic. Download the agenda here.